Fort Pitt Capital Group LLC Has $3.74 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fort Pitt Capital Group LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,633 shares of the company’s stock after buying an additional 504 shares during the period. Fort Pitt Capital Group LLC’s holdings in Johnson & Johnson were worth $3,739,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of JNJ. Dumont & Blake Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 0.3% in the fourth quarter. Dumont & Blake Investment Advisors LLC now owns 20,796 shares of the company’s stock worth $3,033,000 after buying an additional 71 shares during the last quarter. DE Burlo Group Inc. increased its stake in shares of Johnson & Johnson by 3.9% in the fourth quarter. DE Burlo Group Inc. now owns 1,871 shares of the company’s stock worth $273,000 after purchasing an additional 71 shares during the period. Verus Financial Partners Inc. increased its stake in shares of Johnson & Johnson by 1.7% in the fourth quarter. Verus Financial Partners Inc. now owns 4,382 shares of the company’s stock worth $639,000 after purchasing an additional 74 shares during the period. Aries Wealth Management increased its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Aries Wealth Management now owns 27,932 shares of the company’s stock worth $4,025,000 after purchasing an additional 75 shares during the period. Finally, AlphaMark Advisors LLC increased its stake in shares of Johnson & Johnson by 1.3% in the fourth quarter. AlphaMark Advisors LLC now owns 5,799 shares of the company’s stock worth $846,000 after purchasing an additional 75 shares during the period. 69.30% of the stock is owned by institutional investors and hedge funds.

In other Johnson & Johnson news, Director William D. Perez bought 500 shares of Johnson & Johnson stock in a transaction dated Friday, March 13th. The shares were acquired at an average cost of $127.69 per share, with a total value of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael E. Sneed sold 58,128 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $149.39, for a total value of $8,683,741.92. Following the completion of the transaction, the chief operating officer now directly owns 107,511 shares in the company, valued at $16,061,068.29. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

NYSE JNJ traded up $1.22 during trading on Wednesday, reaching $120.41. 5,748,106 shares of the company traded hands, compared to its average volume of 15,632,667. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.01 and a current ratio of 1.26. The stock’s 50 day moving average price is $141.31 and its two-hundred day moving average price is $138.39. The company has a market cap of $293.00 billion, a price-to-earnings ratio of 17.76, a P/E/G ratio of 1.85 and a beta of 0.74. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $154.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.01. The company had revenue of $20.75 billion for the quarter, compared to the consensus estimate of $20.83 billion. Johnson & Johnson had a return on equity of 39.27% and a net margin of 22.18%. The company’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.97 earnings per share. Equities research analysts expect that Johnson & Johnson will post 9.03 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th were issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 3.16%. The ex-dividend date was Monday, February 24th. Johnson & Johnson’s payout ratio is currently 43.78%.

A number of research firms have recently commented on JNJ. Credit Suisse Group dropped their price objective on Johnson & Johnson from $170.00 to $159.00 and set an “outperform” rating on the stock in a research note on Friday, March 6th. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price objective on the stock in a research note on Wednesday, December 18th. Raymond James lifted their price objective on Johnson & Johnson from $147.00 to $161.00 and gave the stock an “outperform” rating in a research note on Thursday, January 23rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $168.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Finally, Morgan Stanley upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $145.00 to $170.00 in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and an average target price of $162.33.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Using other technical indicators with support levels

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.